ReviewCurrent molecular medicine2013
Understanding and targeting osteoclastic activity in prostate cancer bone metastases.
Review in Current molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 62 citations in OpenAlex.
- JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4.Theranostics · 2025Article
- Low-magnitude high-frequency vibration reduces prostate cancer growth and extravasationMechanobiology in medicine · 2024Article
- α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation.Scientific reports · 2024Article
- Prostate cancer bone metastases biology and clinical management (Review).Oncology letters · 2023Review
- Review
- Lipid-Based Nano-Sized Cargos as a Promising Strategy in Bone Complications: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- A Bioreactor for 3DFrontiers in bioengineering and biotechnology · 2022Article
- Prostate adenocarcinoma with osteolytic metastases: Case report and review of the literature.Radiology case reports · 2021Article
- The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report.Acta bio-medica : Atenei Parmensis · 2021Article
- Bone-on-a-chip: microfluidic technologies and microphysiologic models of bone tissue.Advanced functional materials · 2021Article
- Small extracellular vesicles deliver osteolytic effectors and mediate cancer-induced osteolysis in bone metastatic niche.Journal of extracellular vesicles · 2021Article
- Review
- Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p.Journal of extracellular vesicles · 2021Article
- A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy.Frontiers in oncology · 2021Review
- Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner.Journal of extracellular vesicles · 2020Article
- Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.International journal of molecular sciences · 2020Review
- Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.Pigment cell & melanoma research · 2020Article
- Article
- FOXA2 promotes prostate cancer growth in the bone.American journal of translational research · 2020Article
- Bone Health in Men with Prostate Cancer: Review Article.Current osteoporosis reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Bone metastasis is a debilitating side effect of advanced prostatic carcinoma impacting nearly all of the men developing this disease. Even though a majority of these lesions are considered osteoblastic, it is believed that there is an underlying osteolytic component. Lytic processes are governed primarily by osteoclasts, the primary bone resorptive cell. Osteolysis has been implicated in tumor cell seeding and nourishment of tumor growth via development of pro-tumorigenic changes in the microenvironment. Herein, we provide a current view of the processes involved in regulating osteolysis in the presence of prostate cancer bone metastases. Several factors have been implicated in the division, differentiation, and activation of osteoclasts, including, but not limited to, interleukin-6, receptor activator of nuclear factor kappa B ligand (RANKL), osteoprotegerin (OPG), and parathyroid hormone-related protein (PTHrP). Effector molecules in bone resorption play a significant role, such as matrix metalloproteinases (MMPs), cathepsins, and acid secretion. The primary method for treating skeletal events associated with prostate cancer bone metastases has been bisphosphonates. However, a new therapeutic, denosumab, a monoclonal antibody that inhibits RANKL in a mechanism similar to that attributed to the endogenous mediator OPG, has received approval for treatment of skeletally associated metastases. Additional novel targets are continuously being developed for bone metastases. In this review, we describe the processes involved in osteolysis of the prostate cancer bone microenvironment, and introduce therapeutics that may play a role in inhibiting tumor growth leading to increased survival and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.